A Phase III Trial of Afatinib vs Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma After Platinum-Based Chemotherapy
A randomised, open-label, Phase III study to evaluate the efficacy and safety of oral afatinib* vs intravenous (IV) methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum-based therapy.
Trial CT.gov-Identifier: NCT01345682
Squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, that was recurrent and/or metastatic and not amenable for salvage surgery or radiotherapy
Progressive disease after first-line cisplatin or carboplatin (≥2 cycles) for recurrent and/or metastatic disease
No prior treatment with epidermal growth factor receptor (EGFR) inhibitors
Eastern Cooperative Oncology Group performance status of 0–1
Primary outcome measure:
Key secondary outcome measure:
Secondary outcome measures:
LUX-Head & Neck 1 met its primary endpoint of PFS and showed that patients taking afatinib after failure of previous platinum-based chemotherapy experienced a significant delay in tumour growth of 2.6 vs 1.7 months with methotrexate (MTX). This translated into a 20% reduction in risk of disease progression.
OS was not significantly different between afatinib and methotrexate.
DCR was achieved in 49.1% of patients on afatinib vs 38.5% of patients on methotrexate.
Compared with methotrexate, afatinib was associated with delayed time to deterioration of global health status (3.3 vs 2.7 months, p=0.027), pain (3.0 vs 2.3 months, p=0.022) and swallowing (3.8 vs 2.1 months, p=0.004).
Adverse events (AEs) of Grade ≥3 occurred in 67% of patients in the afatinib group compared with 63% in the methotrexate group. The most frequent AEs were:
Neutropenia (Grade 3/4=7%)
Subgroup analysis according to age:
Analysis according to the pre-specified subgroups of patients aged ≥65 years and <65 years showed similar results for efficacy, safety and HRQoL. Advancing age did not adversely affect outcomes following afatinib treatment.
Subgroup analysis according to characteristics linked to HPV negativity:
Post-hoc analyses found that subgroups of patients that had baseline characteristics potentially linked to human papillomavirus (HPV) negativity (i.e. p16-negative disease, primary disease in the larynx, and smoking history ≥10 pack-years) exhibited a greater benefit in PFS with afatinib than with methotrexate.
Afatinib was associated with significant improvements in PFS and had a manageable safety profile.
Machiels J-P, et al. Lancet Oncol 2015;16(5):583–594.
Clement PM, et al. Ann Oncol 2016;27:1585–1593.
Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT01345682 (Accessed: June 2019).
*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information. The efficacy and safety of afatinib in HNSCC has not been established.
Page last updated: September 2017
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue